Neo Ivy Capital Management’s Definium Therapeutics DFTX Stock Holding History

Neo Ivy Capital Management’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.8K	Buy	+315	New	+$7.78K	﹤0.01%	331

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Neo Ivy Capital Management's DFTX Position: Q2 2026 in Review

Neo Ivy Capital Management opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 315 shares worth $14.8K. The stake represents ﹤0.01% of the portfolio and ranks #331 among its holdings.

361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Neo Ivy Capital Management held 315 shares of Definium Therapeutics worth $14.8K as of Q2 2026.
Definium Therapeutics was a new Neo Ivy Capital Management position in Q2 2026.
Definium Therapeutics made up ﹤0.01% of Neo Ivy Capital Management's portfolio in Q2 2026, its #331 holding.
361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Neo Ivy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.